Multiple Sclerosis: Ozanimod Treatment Study

We are investigating how ozanimod affects inflammation in the brain and spinal cord for individuals with Multiple Sclerosis. This study aims to understand its potential benefits and any side effects.

>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesOralNeurology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Zeposia
Zeposia is a prescription medicine used to treat relapsing forms of multiple sclerosis and moderate to severe ulcerative colitis.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Ozanimod
Ozanimod is a substance that helps control the immune system to reduce relapses in relapsing multiple sclerosis and inflammation in ulcerative colitis.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Azienda Ospedaliera Universitaria Integrata Verona
UOC Neurologia B
Verona, Italy
Sponsor: Azienda Ospedaliera Universitaria Integrata Verona
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.